NCT03950154

Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer

Phase III Clinical Study of PD-1 Monoclonal Antibody-activated Autologous Peripheral Blood T-lymphocyte (PD1-T) Combined With XELOX and Bevacizumab in the First-line Treatment of Recurrent and Metastatic Colorectal Cancer

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 198 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the effect and safty of PD-1 monoclonal antibody-activated autologous peripheral blood lymphocyte (PD1-T) combined with XELOX and bevacizumab in the first-line treatment of recurrent and metastatic colorectal cancer. Half of participants receive PD1-T combined with XELOX and bevacizumab, while the other half will receive XELOX and bevacizumab.

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Bevacizumab Injection [Avastin]	Bevacizumab injection
DRUG	Oxaliplatin	Oxaliplatin injection
DRUG	Capecitabine	Capecitabine oral agent
BIOLOGICAL	PD1-T cells	PD1-T cells injection

Timeline

• Start date: 2019-06-01
• Primary completion: 2023-08-01
• Completion: 2023-08-01
• First posted: 2019-05-15
• Last updated: 2023-08-01

Locations

1 site across 1 country: China